1. Home
  2. IPSC vs MURA Comparison

IPSC vs MURA Comparison

Compare IPSC & MURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IPSC
  • MURA
  • Stock Information
  • Founded
  • IPSC 2019
  • MURA 2013
  • Country
  • IPSC United States
  • MURA Ireland
  • Employees
  • IPSC N/A
  • MURA N/A
  • Industry
  • IPSC Medicinal Chemicals and Botanical Products
  • MURA
  • Sector
  • IPSC Health Care
  • MURA
  • Exchange
  • IPSC Nasdaq
  • MURA Nasdaq
  • Market Cap
  • IPSC 43.2M
  • MURA 36.0M
  • IPO Year
  • IPSC 2021
  • MURA N/A
  • Fundamental
  • Price
  • IPSC $0.56
  • MURA $2.09
  • Analyst Decision
  • IPSC Strong Buy
  • MURA Buy
  • Analyst Count
  • IPSC 5
  • MURA 2
  • Target Price
  • IPSC $3.33
  • MURA $6.00
  • AVG Volume (30 Days)
  • IPSC 486.6K
  • MURA 163.9K
  • Earning Date
  • IPSC 11-04-2025
  • MURA 11-12-2025
  • Dividend Yield
  • IPSC N/A
  • MURA N/A
  • EPS Growth
  • IPSC N/A
  • MURA N/A
  • EPS
  • IPSC N/A
  • MURA N/A
  • Revenue
  • IPSC $114,128,000.00
  • MURA N/A
  • Revenue This Year
  • IPSC $1,589.94
  • MURA N/A
  • Revenue Next Year
  • IPSC N/A
  • MURA N/A
  • P/E Ratio
  • IPSC N/A
  • MURA N/A
  • Revenue Growth
  • IPSC 5491.77
  • MURA N/A
  • 52 Week Low
  • IPSC $0.34
  • MURA $0.95
  • 52 Week High
  • IPSC $1.83
  • MURA $4.74
  • Technical
  • Relative Strength Index (RSI)
  • IPSC 60.86
  • MURA 53.24
  • Support Level
  • IPSC $0.48
  • MURA $2.06
  • Resistance Level
  • IPSC $0.51
  • MURA $2.12
  • Average True Range (ATR)
  • IPSC 0.03
  • MURA 0.02
  • MACD
  • IPSC 0.01
  • MURA -0.00
  • Stochastic Oscillator
  • IPSC 67.79
  • MURA 41.67

About IPSC Century Therapeutics Inc.

Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.

About MURA Mural Oncology plc

Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.

Share on Social Networks: